SAN ANTONIO–(BUSINESS WIRE)–$wytc #drugsensingtechnology–Wytec International, Inc. (OTCQB: WYTC) (“Wytec” or the “Company”), a developer of AI-powered public safetySAN ANTONIO–(BUSINESS WIRE)–$wytc #drugsensingtechnology–Wytec International, Inc. (OTCQB: WYTC) (“Wytec” or the “Company”), a developer of AI-powered public safety

Wytec International Has Negotiated an AI-Powered Co-Development Technology Agreement with APEX IP LLC for its Public Safety Platform Technology

2026/02/20 04:16
3 min read

SAN ANTONIO–(BUSINESS WIRE)–$wytc #drugsensingtechnology–Wytec International, Inc. (OTCQB: WYTC) (“Wytec” or the “Company”), a developer of AI-powered public safety solutions, today announced that it is entering into a Co-Development Technology Agreement (the “Technology Agreement”) with Apex Protocol IP LLC (“Apex Protocol”), a Wyoming-based intellectual property holding company owned by Omnia Capital, to co-develop a proprietary AI-powered public safety monitoring platform. “The Technology Agreement represents a significant step in advancing Wytec’s Public Safety platform connected to its MSA with the North Central Council of Governments,” says William Gray, President/CEO of Wytec.

Technology License and Development Agreement

Under the terms of the proposed Technology Agreement, Wytec will co-develop the Apex Protocol with Apex IP LLC executing a Pilot Test scheduled for March 1st, 2026. The Pilot Test will be in conjunction with Wytec’s current Master Service Agreement (MSA) with the North Central Texas Council of Governments including the 90,000+ Civic Marketplace Members consisting of city and county governments, transportation authorities, police stations and independent school districts throughout the United States.

About the APEX Protocol

The Apex Protocol is a purpose-built, AI-powered public safety assessment and monitoring platform. Current development status now includes Key components consisting of a Wytec Public Safety Index (WPSI), a 500-point scoring framework for quantifying institutional safety readiness; a five-protocol assessment system; an AI Safety Intelligence; automated report generation; and a multi-source data enrichment pipeline incorporating over 30 API integrations all supported by an instant Chat GTP voice response Agent called Wyatt AI capable of answering simple or highly technical questions related to Wytec’s AI public safety solutions. The platform is designed to provide standardized, quantifiable safety assessments for K–12 schools, higher education institutions, churches, hospitals, government buildings, and other facilities while currently offering Gunshot and Vape Detection solutions supported by advanced in-building cellular coverage. The pre-launch version of the Apex Protocol can be viewed at https://publicsafety.solutions/.

About Wytec International, Inc.

Wytec International, Inc. (OTCQB: WYTC) is a San Antonio, Texas-based technology company focused on the design, development, and deployment of AI-powered public safety solutions. The Company’s Integrated Public Safety Solutions (IPSS) system combines proprietary Smart Sensors, AI-driven gunshot detection technology, cellular signal enhancement through multiple partnerships, environmental monitoring capabilities, and edge computing infrastructure. To learn more about Wytec, please visit www.wytecintl.ai, call us toll-free at 888-284-4531, or email us at pr@wytecintl.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934 and based on management’s current expectations and beliefs and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Contacts

1-888-284-4531
pr@wytecintl.com

Market Opportunity
ApeX Protocol Logo
ApeX Protocol Price(APEX)
$0.3258
$0.3258$0.3258
-0.42%
USD
ApeX Protocol (APEX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03